Skip to main
NDRA
NDRA logo

NDRA Stock Forecast & Price Target

NDRA Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

ENDRA Life Sciences Inc. is poised for significant growth due to the anticipated FDA approval of its TAEUS technology, which offers a novel method for the early diagnosis and monitoring of liver diseases like NAFLD and NASH. The company's NPV analysis indicates a substantial upside potential for its stock, reflecting confidence in the marketability and practical application of its innovative diagnostic tools. Furthermore, TAEUS is expected to provide a more accurate and cost-effective alternative to existing technologies, enabling broader adoption and improved patient care in the healthcare landscape.

Bears say

ENDRA Life Sciences Inc reported a net loss of $1.2 million, translating to an earnings per share (EPS) of $(1.71), which reflects a deviation from earlier estimates of $(2.27). The company faces significant risks including liquidity concerns, the potential failure to demonstrate safety and efficacy for its product candidates in clinical trials, challenges in gaining regulatory approvals, and difficulties in commercialization and reimbursement. Additionally, the competitive landscape and macroeconomic factors may impact investor sentiment, contributing to a cautious outlook on the company’s financial stability and future performance.

NDRA has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ENDRA Life Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ENDRA Life Sciences (NDRA) Forecast

Analysts have given NDRA a Strong Buy based on their latest research and market trends.

According to 1 analysts, NDRA has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ENDRA Life Sciences (NDRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.